13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Neuro-ophthalmology and Auditory Neurology
Neuro-ophthalmology and auditory neurology focus on understanding and treating disorders related to vision and hearing that stem from neurological causes. Neuro-ophthalmology investigates conditions like optic neuritis, papilledema, and visual disturbances from neurological diseases, while Auditory Neurology centers on disorders such as hearing loss, tinnitus, and balance issues due to neural dysfunctions. With advancements in diagnostic imaging and electrophysiological testing, these fields are uncovering complex mechanisms underlying sensory disorders. Ongoing research is leading to new interventions, including neuroplasticity-based therapies and neural stimulation techniques, offering hope for improving or restoring sensory function in affected patients.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States